Clearside Biomedical (CLSD) Stock Price, News & Analysis

Company Overview

Clearside Biomedical, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for diseases affecting the back of the eye. The company’s proprietary SCS Microinjector® platform enables targeted delivery of therapeutics into the suprachoroidal space, a potential route to enhance local drug exposure while minimizing off-target effects. Clearside’s approach is designed to address a range of retinal disorders by directly depositing medication adjacent to choroid and retina.

The company’s lead approved product is XIPERE® (triamcinolone acetonide injectable suspension), which has received U.S. Food and Drug Administration clearance for the treatment of macular edema associated with uveitis. In addition to XIPERE, Clearside has advanced several pipeline candidates, including CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration and other small-molecule and biologic programs leveraging the suprachoroidal route. These programs are in various stages of clinical development, targeting indications such as diabetic macular edema and wet AMD.

Founded in 2010 and headquartered in Alpharetta, Georgia, Clearside Biomedical completed its initial public offering on the Nasdaq Stock Market under the ticker “CLSD.” The company is led by President and Chief Executive Officer Samir Melhem, who has overseen clinical and regulatory milestones, including FDA approval of XIPERE. Clearside continues to explore both U.S. and ex-U.S. partnerships to expand patient access to its suprachoroidal therapies.

Key Stats

• Today's Range: $3.70 to $4.43
• 50-Day Range: $4.79 to $13.27
• 52-Week Range: $3.70 to $24.75
• Volume: 234,040 shs
• Average Volume: 118,290 shs
• Market Capitalization: $305.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $63.00
• Consensus Rating: Hold

Clearside Biomedical Stock Analysis - MarketRank™

Clearside Biomedical scored higher than 47% of companies evaluated by MarketBeat, and ranked 662nd out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Clearside Biomedical has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.

Upside Potential

Clearside Biomedical has a consensus price target of $63.00, representing about 1,507.6% upside from its current price of $3.92.

Amount of Analyst Coverage

Clearside Biomedical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.48) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Clearside Biomedical is -10.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Clearside Biomedical is -10.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.35% of the float of Clearside Biomedical has been sold short.

Short Interest Ratio / Days to Cover

Clearside Biomedical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Clearside Biomedical has recently decreased by 4.44%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Clearside Biomedical does not currently pay a dividend.

Dividend Growth

Clearside Biomedical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.35% of the float of Clearside Biomedical has been sold short.

Short Interest Ratio / Days to Cover

Clearside Biomedical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Clearside Biomedical has recently decreased by 4.44%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.03

News Sentiment

Clearside Biomedical has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Clearside Biomedical this week, compared to 2 articles on an average week.

Search Interest

12 people have searched for CLSD on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.

MarketBeat Follows

3 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Clearside Biomedical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.70% of the stock of Clearside Biomedical is held by insiders.

Percentage Held by Institutions

Only 18.75% of the stock of Clearside Biomedical is held by institutions.

CLSD Stock Analysis - Frequently Asked Questions

How have CLSD shares performed this year?

Clearside Biomedical's stock was trading at $14.25 at the start of the year. Since then, CLSD stock has decreased by 72.5% and is now trading at $3.9190.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) posted its quarterly earnings results on Friday, August, 8th. The company reported ($0.90) EPS for the quarter, topping analysts' consensus estimates of ($1.80) by $0.90. The company had revenue of $0.49 million for the quarter, compared to analysts' expectations of $0.50 million.

When did Clearside Biomedical's stock split?

Shares of Clearside Biomedical reverse split on Monday, September 15th 2025.The 1-15 reverse split was announced on Thursday, September 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Clearside Biomedical IPO?

Clearside Biomedical (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Who are Clearside Biomedical's major shareholders?

Top institutional shareholders of Clearside Biomedical include Bridgeway Capital Management LLC (0.26%). Insiders that own company stock include Bradford T Whitmore, George M Lasezkay, Charles A Deignan, Thomas Ciulla, Ngai Hang Victor Chong and Benjamin R Yerxa.
View institutional ownership trends.

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Clearside Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), NVIDIA (NVDA), T2 Biosystems (TTOO), Advanced Micro Devices (AMD) and (ZLTQ) (ZLTQ).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLSD
• CIK: 1539029
• Web: www.clearsidebio.com
• Phone: (678) 270-3631
• Fax: 678-270-4033
• Employees: 30
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Clearside Biomedical: $63.00
• High Price Target: $90.00
• Low Price Target: $30.00
• Potential Upside/Downside: +19,618.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.35 million
• Net Margins: -665.19%
• Pretax Margin: -648.06%
• Return on Equity: N/A
• Return on Assets: -124.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.87
• Quick Ratio: 3.87

Sales & Book Value

• Annual Sales: $1.66 million
• Price / Sales: 15.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.51) per share
• Price / Book: -0.63

Miscellaneous

• Outstanding Shares: 78,510,000
• Free Float: 73,250,000
• Market Cap: $25.08 million
• Optionable: Optionable
• Beta: 2.11